A Retrospective Review of the Clinical Experience of Linezolid with or Without Rifampicin in Prosthetic Joint Infections Treated with Debridement and Implant Retention

Infectious Diseases and Therapy

Volumn 3, Issue 2, 2014, Pages 235-243

  Morata, Laura ^a   Senneville, Eric ^b   Bernard, Louis ^c   Nguyen, Sophie ^b   Buzelé, Rodolphe ^c   Druon, Jérome ^d   Tornero, Eduard ^a   Mensa, Josep ^a   Soriano, Alex ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d Regional French Referent Center for Osteo articular Infection   (France)

Author keywords

Debridement; Infectious diseases; Linezolid; Prosthetic joint infection; Rifampicin; Treatment outcome

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; LINEZOLID; RIFAMPICIN;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DEBRIDEMENT; DIABETES MELLITUS; DIARRHEA; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTIOUS ARTHRITIS; KNEE PROSTHESIS; MALE; NAUSEA; OBSERVATIONAL STUDY; PROSTHESIS FIXATION; PROSTHETIC JOINT INFECTION; PSEUDOMONAS AERUGINOSA; RELAPSE; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; TREATMENT RESPONSE; VOMITING;

STAPHYLOCOCCUS;

EID: 84977100637     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0032-z     Document Type: Article

References (27)

1. Cobo J, Miguel LGS, Euba G, et al. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. Clin Microbiol Infect. 2011;17:1632–7.
2. Vilchez F, Martínez-Pastor JC, Garcia-Ramiro S, et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin Microbiol Infect. 2011;17:439–44.
3. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279:1537–41.
4. Lora-Tamayo J, Murillo O, Iribarren JA, et al. A large multicenter study of methicillin susceptible- and methicillin resistant-Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2012;56:182–94.
5. Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis. 2011;53:334–40.
6. Bernard L, Legout L, Zürcher-Pfund L, et al. Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J Infect. 2010;61:125–32.
7. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother. 2003;51(Suppl 2):ii9–16.
8. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51(Suppl 2):ii17–25.
9. Kutscha-Lissberg F, Hebler U, Muhr G, Köller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2003;47:3964–6.
10. Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother. 2009;53:1142–8.
11. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid. In silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229–36.
12. Egle H, Trittler R, Kümmerer K, Lemmen SW. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther. 2005;77:451–3.
13. Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis. 2012;44:548–50.
14. Tornero E, García-Oltra E, García-Ramiro S, et al. Prosthetic joint infections due to Staphylococcus aureus and coagulase-negative staphylococci. Int J Artif Organs. 2012;35:884–92.
15. Bassetti M, Vitale F, Melica G, et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005;55:387–90.
16. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis. 2007;59:173–9.
17. Bradbury T, Fehring TK, Taunton M, et al. The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components. J Arthroplasty. 2009;24:101–4.
18. Legout L, Valette M, Dezeque H, et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother. 2010;65:2224–30.
19. Soriano A, Gómez J, Gómez L, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis. 2007;26:353–6.
20. Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother. 1994;33:959–67.
21. Nguyen S, Pasquet A, Legout L, et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect. 2009;15:1163–9.
22. Gómez J, Canovas E, Baños V, et al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother. 2011;55:4308–10.
23. Brandt CM, Sistrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis. 1997;24:914–9.
24. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17:479–501.
25. Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis. 2009;64:191–201.
26. Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related hematological toxicity in patients with Gram-positive infections. Int J Antimicrob Agents. 2013;41:586–9.
27. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67:2034–42.